• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial

摘要:

Background:The efficacy and safety of telmisartan combined with clopidogrel,leflunomide,or both drugs for immunoglobulin A nephropathy (IgAN) are unclear.This study was designed to evaluate the efficacy and safety of telmisartan combined with clopidogrel,leflunomide,or both drugs for IgAN.Methods:It is a multicenter,prospective,double-dummy randomized controlled trial.Primary IgAN patients were recruited in 13 renal units across Beijing,China,from July 2010 to June 2012.After a 4-week telmisartan (80 mg/d) wash-in,400 patients continuing on 80 mg/d telmisartan were randomly assigned to additionally receive placebo (Group A),50 mg/d clopidogrel (Group B),20 mg/d leflunomide (Group C),or 50 mg/d clopidogrel and 20 mg/d leflunomide (Group D).The 24-week intervention was completed by 360 patients.The primary endpoint was change in 24-h proteinuria at 24 weeks.A linear mixed-effect model was used to analyze the changes at 4,12,and 24 weeks.Generalized estimating equations were used to evaluate changes in hematuria grade.This trial was registered at the Chinese Clinical Trial Registry.Results:The effects of telmisartan combined with lefiunomide on changes in proteinuria (0.36 [95% confidence interval (CI) 0.18-0.55] g/d,P < 0.001),in serum uric acid (76.96 [95% CI57.44-96.49] μmol/L,P < 0.001),in serum creatinine (9.49 [95% CI 6.54-12.44] μmol/L,P < 0.001),and in estimated glomerular filtration rate (-6.72 [95% CI-9.46 to-3.98] ml·min-1· 1.73 m-2,P < 0.001) were statistically significant,whereas they were not statistically significant on changes in systolic and diastolic blood pressure and weight (P > 0.05).Telmisartan combined with clopidogrel had no statistical effect on any outcome,and there was no interaction between the interventions.No obvious adverse reactions were observed.Conclusions:Telmisartan combined with leflunomide,not clopidogrel,is safe and effective for decreasing proteinuria in certain IgAN patients.

更多
作者单位: Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China [1] Department of Nephrology, PLA Army General Hospital, Beijing 100700, China [2] Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China [3] Department of Nephrology, General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China [4]
期刊: 《中华医学杂志(英文版)》2016年129卷16期 1894-1903页 SCIMEDLINEISTICCSCDBP
栏目名称: Original Articles
DOI: 10.4103/0366-6999.187848
发布时间: 2016-09-21
基金项目:
the grants from National Key Technology Research and Development Program from National High Technology Research and Development Program of China two grants from National Clinical Research Center for Kidney Disease from the Science and Technology Project of Beijing,China
翻译满意度评价:
提交
  • 浏览:50
  • 下载:20

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷